Abstract

Dr. Diksha Thakur*, Dr. Rajnikant Rohila

ABSTRACT

Amavata is a chronic, debilitating disease characterized by joint pain (Sandhishula), swelling (Sandhishotha), and stiffness (Stambha). It closely correlates with Rheumatoid Arthritis (RA) in modern medicine. Conventional therapies often provide only temporary relief and carry risks of long-term adverse effects. Aim: This study evaluates the efficacy of Mustadi Ghanvati in Amavata. Materials and Methods: An open-label clinical trial was conducted on 30 registered patients (28 completed). Patients were administered 500 mg of Mustadi Ghanvati thrice daily (TDS) for 45 days after a 3-night preparatory course of Eranda Sneha. Results: Significant clinical improvement (p < 0.001) was observed in all subjective parameters, including pain (48% reduction) and swelling. Objective markers such as ESR, CRP, RA Factor, and Anti-CCP also showed statistically significant reductions. The statistical significance of the data was analyzed using the Wilcoxon Signed Rank Test for subjective parameters and the Paired t-test for objective biochemical markers. Conclusion: Mustadi Ghanvati is an effective, safe, and economical formulation for managing Amavata by addressing the root causes of Ama and Vata vitiation.